Fulgent Genetics, Inc. - Common Stock (FLGT)

The next-generation diagnostics specialist had a beat-and-raise second quarter.

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Fulgent Genetics exceeded expectations in the fourth quarter of 2024, showcasing robust revenue growth and a GAAP loss.

Fulgent Genetics Inc (NASDAQ: FLGT) reported Q2 sales of $68 million, beating the consensus estimate of $62.68 million.<

FLGT stock results show that Fulgent Genetics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Digital health stocks are becoming increasingly relevant as more and more people seek greater control over their health.

Companies Reporting Before The Bell • Arcutis Biotherapeutics (NASDAQ:ARQT) is expected to report quarterly loss at $0.86 per share on revenue of $32.83 million.

Companies Reporting Before The Bell • WPP (NYSE:WPP) is projected to report earnings for its first quarter. • Anglogold Ashanti (NYSE:AU) is likely to report earnings for its first quarter.

Fulgent is moving past its pandemic-era business, and that's a good thing.

Neither has a traditional business model, but that could be an asset for both.

Both are experiencing a bit of a hangover from declining COVID-19-related sales.